Arbutus to Participate in Upcoming Investor Conferences
September 26 2019 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that the Company will be participating in the following
investor conferences in October 2019:
Cantor Fitzgerald Global Healthcare
Conference – New York Friday, October 4, 2019, 1:10 PM
ETPresentation: William H. Collier
Chardan Genetic Medicines Conference – New
YorkMonday, October 7, 2019, 8:00 AM ETFireside Chat:
William H. Collier and Dr. Gaston Picchio
Live webcasts of the presentations can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com. A replay of the webcasts will be
available for 90 days following the live
presentations.
About Arbutus
Arbutus Biopharma Corporation is a
publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated
to discovering, developing, and commercializing a cure for patients
suffering from chronic Hepatitis B infection. Arbutus is developing
multiple drug candidates, each of which have the potential to
improve upon the standard of care and contribute to a curative
combination regimen. For more information, visit
www.arbutusbio.com.
Contact Information
InvestorsWilliam H. Collier President and CEO
Phone: 604-419-3200 Email: ir@arbutusbio.com
MediaPam Murphy Investor Relations Consultant
Phone: 604-419-3200 Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024